Five Prime Therapeutics, Inc. (NASDAQ:FPRX) is on recovery track with 21.25% gain from a 1-year low price of $21.41. The company lost -9.95% to attain the price of $25.96 on 11/13/2017. Throughout the recent session, the prices were hovering between $25.66 and $28.96. These shares are 138.6% off its target price of $61.94 and the current market capitalization stands at $723.51M. The recent change has given its price a -33.31% deficit over SMA 50 and -57.43% deficit over its 52-week high. The stock witnessed -40.24% declines, -6.48% declines and -15.63% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found FPRX’s volatility during a week at 29.07% and during a month it has been found around 10.56%.Five Prime Therapeutics, Inc. (FPRX) Top Holders
Institutional investors currently hold around $703 million or 85.9% in FPRX stock. Look at its top three institutional owners. Fmr Llc owns $124.48 million in Five Prime Therapeutics, Inc., which represents roughly 17.21% of the company’s market cap and approximately 17.71% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 2,923,140 shares of the stock are valued at $84.27 million. The third largest holder is Adage Capital Partners Gp, L.L.C., which currently holds $71.9 million worth of this stock and that ownership represents nearly 9.94% of its market capitalization.
At the end of 06/30/2017 reporting period, 48 institutional holders increased their position in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by some 1,671,983 shares, 83 decreased positions by 1,816,645 and 28 held positions by 20,897,593. That puts total institutional holdings at 24,386,221 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 312,544 shares while 35 institutional investors sold out their entire positions totaling 875,850 shares.Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Insider Trades
Multiple company employees have indulged in significant insider trading. Five Prime Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Ringo William R has sold 600 shares of Five Prime Therapeutics, Inc. (FPRX) in trading session dated Nov. 01, 2017. These shares are worth $27,198 and were traded at $45.33 each. The SEC filing shows that Ringo William R performed a sale of 1,800 shares. The Director disposed these shares by way of transaction on Oct. 02, 2017. The company’s shares were given away at $40.26 per share worth to an income of some $72,468 on account of Ringo William R.
Director, Ringo William R, sold 2,000 common shares of Five Prime Therapeutics, Inc. (FPRX) in the open market. In a transaction dated Sep. 28, 2017, the shares were put up for sale at an average price of $38, raking in a sum of $76,000.
In the transaction dated Mar. 01, 2017, the great number of shares disposed came courtesy the Director; Ringo William R disposed a total of 500 shares at an average price of $46.73, amounting to approximately $23,365.Five Prime Therapeutics, Inc. (FPRX) Analyst Guide
Several analysts have released their opinion on Five Prime Therapeutics, Inc. (NASDAQ:FPRX), with 5 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.17 average brokerage recommendation.